Visão geral da empresa
A biotechnology enterprise, Pluri Inc. engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies, with a specific focus on placenta-based cell therapy product candidates for treating inflammatory conditions, muscle injuries, and other applications. The company operates within the healthcare sector, specifically the biotechnology industry, which implies a business model reliant on scientific innovation, regulatory approvals, and long-term clinical validation rather than immediate consumer demand cycles. Currently, the organization employs 127 individuals and holds a market capitalization of $32.56M, with trailing twelve-month revenue of $1.34M. These financial dimensions indicate that Pluri Inc. is a micro-cap entity with limited operational scale, reflecting a position typical of early-stage biotech firms that prioritize R&D expenditure over profit generation and currently serve a niche market within the broader healthcare ecosystem.
Saúde financeira
Pluri Inc. reported total revenue of $1.34M over the trailing twelve months, yet recorded a net income loss of $-26,138,000 and an EBITDA loss of $-24,435,000, revealing a cost structure where operating expenses significantly exceed revenue generation. The company's free cash flow stands at $-14,348,750, which indicates a substantial consumption of liquidity that limits immediate financial flexibility for capital returns or aggressive debt repayment. Margins for the company are characterized by a gross margin of 40.6%, contrasting sharply with an operating margin of -3285.9% and a profit margin of 0.0%, suggesting that while the cost of goods sold is managed relative to sales, high overhead costs in research and administration are eroding profitability to a degree where operating losses dwarf revenue. In terms of leverage, the company holds $12.48M in cash against total debt of $34.94M, and with a debt-to-equity ratio listed as N/A due to the company's financial position, the balance sheet appears leveraged rather than conservative. The current ratio of 0.43 further signals potential short-term liquidity constraints, as current assets are less than half of current liabilities. Return on Equity and Return on Assets metrics are reported as N/A and -50.6% respectively, indicating that the management's current strategy is resulting in a negative return on the assets deployed, a common but risky characteristic of biotechnology firms burning through capital to achieve product milestones.
Avaliação de valorização
Valuation metrics for Pluri Inc. present a complex picture given the lack of traditional profitability, with a P/E Ratio (TTM) of N/A and a Forward P/E of -1.71, implying that future earnings expectations are either negative or not yet materialized in a way that supports a standard multiple. The price-to-book ratio is reported as -2.21, which indicates that the market values the company at a negative multiple of its book value, a situation often seen in biotech firms where intangible assets like intellectual property are not fully captured on the balance sheet or where liabilities exceed tangible assets. Alternative valuation metrics show a price-to-sales ratio of 24.32 and an EV/EBITDA of -2.47, suggesting the market is pricing the company based on its revenue potential and growth prospects in the cell therapy space rather than current earnings power. Price action over the last year has seen the stock trade between a 52-week high of $7.13 and a 52-week low of $2.82, placing the current valuation somewhere within this volatile range relative to recent historical performance. The stock exhibits a beta of 0.73, meaning its price volatility is lower than the broader market, offering a degree of stability that is somewhat unusual for small-cap biotechnology stocks but consistent with its specific risk profile.
Growth & Income
Revenue growth for Pluri Inc. is recorded at 7.0% year-over-year, while earnings growth is N/A due to the company's continued losses, indicating that top-line expansion is occurring without a corresponding improvement in profitability. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available cash flow is reinvested into research, development, and operational scaling rather than distributed to shareholders. This reinvestment strategy is typical for biotechnology companies that require significant capital infusion to advance clinical trials and secure regulatory clearance for their cell-based products. Consequently, the overall growth and income profile of Pluri Inc. is defined by moderate revenue expansion coupled with significant capital burn and no income distribution, relying entirely on external financing or future successful product launches to alter its financial trajectory.